Radiological regression of metastatic renal carcinoma after biological treatment with Sunitinib – case report and literature review

Czech version

Authors: Vladimír Šámal ^1,2; Igor Richter ³; Vít Paldus ¹; Tomáš Jirásek ⁴; Jan Mečl ¹
Authors‘ workplace: Urologické oddělení, Krajská nemocnice Liberec, a. s., Liberec ¹; Urologická klinika FN a LF UK, Hradec Králové ²; Onkologické oddělení, Krajská nemocnice Liberec, a. s., Liberec ³; Oddělení patologie, Krajská nemocnice Liberec, a. s., Liberec ⁴
Published in: Ces Urol 2019; 23(4): 341-346
Category: Case report

Overview

Renal cell carcinoma is a metastatic disease in up to 21% of patients at the time of diagnosis. Modern targeted therapy and immunotherapy a have significantly improved the prognosis of patients with metastatic disease. We present a case report of a patient with metastatic renal cell carcinoma, multiple lung and pleural metastases. There was complete radiological regression of lung metastases of seven months duration after sunitinib treatment. Only microscopic bearings of clear cell renal carcinoma were found in the pathological specimen after nephrectomy.

Keywords:

targeted therapy – imunotherapy – Metastatic renal cell carcinoma – sunitinib

Sources

1. Dabestani S, Thorstenson A, Lindblad P, et al. Renal cell carcinoma recurrences and metastases in primary nonmetastatic patients: a population‑based study. World J Urol 2016; 34(8): 1081–1086.

2. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon‑alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002; 20(1): 289–296.

3. Fyfe G, Fisher RI, Rosenberg SA, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high ‑dose recombinant interleukin‑2 therapy. J Clin Oncol 1995; 13(3): 688–696.

4. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear‑cell renal‑cell carcinoma. N Engl J Med 2007; 356(2): 125–134.

5. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. Jama 2006; 295(21): 2516–2524.

6. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27(22): 3584–3590.

7. Albiges L, Powles T, Staehler M, et al. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First‑line Treatment of Metastatic Clear ‑cell Renal Cell Carcinoma. Eur Urol 2019; 76(2): 151–156.

8. Gong J, Maia MC, Dizman N, Govindarajan A, Pal SK. Metastasis in renal cell carcinoma: Biology and implications for therapy. Asian Journal of Urology 2016; 3(4): 286–292.

9. Zhou L, Liu XD, Sun M, et al. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene 2016; 35(21): 2687–2697.

10. Callea M, Albiges L, Gupta M, et al. Differential Expression of PD ‑L1 between Primary and Metastatic Sites in Clear‑Cell Renal Cell Carcinoma. Cancer Immunol Res 2015; 3(10): 1158–1164.

11. Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006; 24(1): 25–35.

12. Najjar YG, Mittal K, Elson P, et al. A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma. Eur J Cancer 2014; 50(6): 1084–1089.

13. Staehler M, Haseke N, Zilinberg E, et al. Complete remission achieved with angiogenic therapy in metastatic renal cell carcinoma including surgical intervention. Urol Oncol 2010; 28(2): 139–144.

14. Mejean A, Ravaud A, Thezenas S, et al. Sunitinib Alone or after Nephrectomy in Metastatic Renal ‑Cell Carcinoma. N Engl J Med 2018; 379(5): 417–427.

15. Bex A, Mulders P, Jewett M, et al. Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial. JAMA Oncol 2019; 5(2): 164–170.

16. Dabestani S, Marconi L, Hofmann F, et al. Local treatments for metastases of renal cell carcinoma: a systematic review. Lancet Oncol 2014; 15(12): e549–561.